{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T22:40:23Z","timestamp":1789166423389,"version":"build-2803163510"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T00:00:00Z","timestamp":1667952000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100014848","name":"Arnold Ventures","doi-asserted-by":"publisher","award":["NA"],"award-info":[{"award-number":["NA"]}],"id":[{"id":"10.13039\/100014848","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Med"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>In the adjuvant setting of cancer treatment, de-escalation strategies have the goal of omitting or minimizing treatment in patients, without compromising outcomes. Historically, eligibility for adjuvant treatment solely relied on the patient\u2019s clinical and tumor\u2019s pathological characteristics. At the turn of the century, based on new biological understanding, molecular-based strategies were tested and sometimes implemented.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Main body<\/jats:title>\n                <jats:p>However, we illustrate how molecularly based de-escalation strategies may paradoxically lead to overtreatment. This may happen when the novel approach is tested in lieu of standard management and may not yield the same results when being implemented in addition to usual practice. In the DYNAMIC trial, adjuvant chemotherapy decision in stage II colon cancer was compared between a circulating tumor DNA (ctDNA)-based approach and the standard care. We show this may result in more patients receiving oxaliplatin-based chemotherapy and may expose a similar proportion of patients to chemotherapy if the novel strategy is implemented in addition to usual practice. The other potential risk is undertreatment. We provide an illustration of early breast cancer, where the decision of adjuvant chemotherapy based on the gene expression signature MammaPrint may lead to inferior outcomes as compared with the clinico-pathologic strategy. This may also happen when non-inferiority designs have large margins. Among solutions, it should be acknowledged that clinico-pathological features, like T4 in colon cancer, may not be abandoned and replaced by novel strategies in real-life practice. Therefore, novel strategies should be tested in addition to standard of care, and not <jats:italic>in lieu of<\/jats:italic>. Second, de-escalation trials should focus on the settings where the standard of care has a widespread agreement. This would avoid the risk of testing non-inferiority against an ineffective therapy, which guarantees successes without providing informative data.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>Simply because a molecular test is rational does not mean it can improve patient outcomes. Here, we highlight how molecular test-based strategies may result in either overtreatment or undertreatment. In the rapidly evolving field of medicine, where technological advances may be transformative, our piece highlights scientific pitfalls to be aware of when considering running such trials or before implementing novel strategies in daily practice.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12916-022-02589-6","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T01:02:39Z","timestamp":1667955759000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Molecular testing to deliver personalized chemotherapy recommendations: risking over and undertreatment"],"prefix":"10.1186","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6936-5783","authenticated-orcid":false,"given":"Timoth\u00e9e","family":"Olivier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinay","family":"Prasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,9]]},"reference":[{"key":"2589_CR1","doi-asserted-by":"publisher","first-page":"4120","DOI":"10.1200\/JCO.20.01382","volume":"38","author":"MJ Piccart","year":"2020","unstructured":"Piccart MJ, Hilbers FS, Bliss JM, Caballero C, Frank ES, Renault P, et al. Road map to safe and well-designed de-escalation trials of systemic adjuvant therapy for solid tumors. J Clin Oncol. 2020;38:4120\u20139.","journal-title":"J Clin Oncol"},{"issue":"132","key":"2589_CR2","first-page":"338","volume":"1997","author":"B Cady","year":"1960","unstructured":"Cady B. Basic principles in surgical oncology. Arch Surg Chic Ill. 1960;1997(132):338\u201346.","journal-title":"Arch Surg Chic Ill"},{"key":"2589_CR3","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1053\/j.seminoncol.2019.01.002","volume":"46","author":"M Burotto","year":"2019","unstructured":"Burotto M, Wilkerson J, Stein WD, Bates SE, Fojo T. Adjuvant and neoadjuvant cancer therapies: a historical review and a rational approach to understand outcomes. Semin Oncol. 2019;46:83\u201399.","journal-title":"Semin Oncol"},{"key":"2589_CR4","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/1477-7525-10-14","volume":"10","author":"I Chopra","year":"2012","unstructured":"Chopra I, Kamal KM. A systematic review of quality of life instruments in long-term breast cancer survivors. Health Qual Life Outcomes. 2012;10:14.","journal-title":"Health Qual Life Outcomes"},{"key":"2589_CR5","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/nrclinonc.2017.31","volume":"14","author":"V Prasad","year":"2017","unstructured":"Prasad V, De Jes\u00fas K, Mailankody S. The high price of anticancer drugs: origins, implications, barriers, solutions. Nat Rev Clin Oncol. 2017;14:381\u201390.","journal-title":"Nat Rev Clin Oncol"},{"key":"2589_CR6","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.1377\/hlthaff.2012.1263","volume":"32","author":"S Ramsey","year":"2013","unstructured":"Ramsey S, Blough D, Kirchhoff A, Kreizenbeck K, Fedorenko C, Snell K, et al. Washington state cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff Proj Hope. 2013;32:1143\u201352.","journal-title":"Health Aff Proj Hope"},{"key":"2589_CR7","doi-asserted-by":"publisher","first-page":"980","DOI":"10.1200\/JCO.2015.64.6620","volume":"34","author":"SD Ramsey","year":"2016","unstructured":"Ramsey SD, Bansal A, Fedorenko CR, Blough DK, Overstreet KA, Shankaran V, et al. Financial insolvency as a risk factor for early mortality among patients with cancer. J Clin Oncol. 2016;34:980\u20136.","journal-title":"J Clin Oncol"},{"key":"2589_CR8","doi-asserted-by":"publisher","first-page":"1184","DOI":"10.6004\/jnccn.2019.7305","volume":"17","author":"GL Smith","year":"2019","unstructured":"Smith GL, Lopez-Olivo MA, Advani PG, Ning MS, Geng Y, Giordano SH, et al. Financial burdens of cancer treatment: a systematic review of risk factors and outcomes. J Natl Compr Cancer Netw. 2019;17:1184\u201392.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2589_CR9","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.16058","volume":"5","author":"I Mousavi","year":"2022","unstructured":"Mousavi I, Olivier T, Prasad V. Cost per event averted in cancer trials in the adjuvant setting from 2018 to 2022. JAMA Netw Open. 2022;5:e2216058.","journal-title":"JAMA Netw Open"},{"key":"2589_CR10","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1200\/JCO.19.02309","volume":"38","author":"KH Allison","year":"2020","unstructured":"Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL, et al. Estrogen and progesterone receptor testing in breast cancer: ASCO\/CAP Guideline Update. J Clin Oncol. 2020;38:1346\u201366.","journal-title":"J Clin Oncol"},{"key":"2589_CR11","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff AC, Hammond MEH, Allison KH, Harvey BE, Mangu PB, Bartlett JMS, et al. Human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists Clinical Practice Guideline focused update. J Clin Oncol. 2018;36:2105\u201322.","journal-title":"J Clin Oncol"},{"key":"2589_CR12","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.1200\/JCO.2002.20.4.1043","volume":"20","author":"NM Lindor","year":"2002","unstructured":"Lindor NM, Burgart LJ, Leontovich O, Goldberg RM, Cunningham JM, Sargent DJ, et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol. 2002;20:1043\u20138.","journal-title":"J Clin Oncol"},{"key":"2589_CR13","doi-asserted-by":"publisher","first-page":"1232","DOI":"10.1093\/annonc\/mdz116","volume":"30","author":"C Luchini","year":"2019","unstructured":"Luchini C, Bibeau F, Ligtenberg MJL, Singh N, Nottegar A, Bosse T, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1\/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232\u201343.","journal-title":"Ann Oncol"},{"issue":"49","key":"2589_CR14","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1016\/j.ejca.2013.02.021","volume":"2013","author":"F Chibon","year":"2013","unstructured":"Chibon F. Cancer gene expression signatures - the rise and fall? Eur J Cancer. 2013;(49):2000\u20139.","journal-title":"Eur J Cancer"},{"key":"2589_CR15","doi-asserted-by":"publisher","first-page":"595","DOI":"10.1038\/nrclinonc.2017.74","volume":"14","author":"M Kwa","year":"2017","unstructured":"Kwa M, Makris A, Esteva FJ. Clinical utility of gene-expression signatures in early stage breast cancer. Nat Rev Clin Oncol. 2017;14:595\u2013610.","journal-title":"Nat Rev Clin Oncol"},{"key":"2589_CR16","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1158\/2159-8290.CD-15-1483","volume":"6","author":"C Alix-Panabi\u00e8res","year":"2016","unstructured":"Alix-Panabi\u00e8res C, Pantel K. Clinical applications of circulating tumor cells and circulating tumor DNA as liquid biopsy. Cancer Discov. 2016;6:479\u201391.","journal-title":"Cancer Discov"},{"key":"2589_CR17","doi-asserted-by":"publisher","first-page":"2261","DOI":"10.1056\/NEJMoa2200075","volume":"386","author":"J Tie","year":"2022","unstructured":"Tie J, Cohen JD, Lahouel K, Lo SN, Wang Y, Kosmider S, et al. Circulating tumor DNA analysis guiding adjuvant therapy in stage II colon cancer. N Engl J Med. 2022;386:2261\u201372.","journal-title":"N Engl J Med"},{"key":"2589_CR18","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1016\/j.annonc.2020.06.022","volume":"31","author":"G Argil\u00e9s","year":"2020","unstructured":"Argil\u00e9s G, Tabernero J, Labianca R, Hochhauser D, Salazar R, Iveson T, et al. Localised colon cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann Oncol. 2020;31:1291\u2013305.","journal-title":"Ann Oncol"},{"key":"2589_CR19","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1200\/JCO.21.02538","volume":"40","author":"NN Baxter","year":"2022","unstructured":"Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, et al. Adjuvant therapy for stage II colon cancer: ASCO guideline update. J Clin Oncol. 2022;40:892\u2013910.","journal-title":"J Clin Oncol"},{"issue":"137","key":"2589_CR20","doi-asserted-by":"publisher","first-page":"148","DOI":"10.1016\/j.ejca.2020.06.036","volume":"2020","author":"A Teufel","year":"2020","unstructured":"Teufel A, Gerken M, F\u00fcrst A, Ebert M, Hohenthanner I, Klinkhammer-Schalke M. Benefit of adjuvant chemotherapy in high-risk colon cancer: a 17-year population-based analysis of 6131 patients with Union for International Cancer Control stage II T4N0M0 colon cancer. Eur J Cancer. 2020;(137):148\u201360.","journal-title":"Eur J Cancer"},{"key":"2589_CR21","unstructured":"Jeremy Jones sur Twitter. Twitter. https:\/\/twitter.com\/Jcj84Jeremy\/status\/1533448970726408192. Accessed 8 Sep 2022."},{"key":"2589_CR22","doi-asserted-by":"publisher","first-page":"2699","DOI":"10.1200\/JCO.2013.49.1514","volume":"31","author":"F Mols","year":"2013","unstructured":"Mols F, Beijers T, Lemmens V, van den Hurk CJ, Vreugdenhil G, van de Poll-Franse LV. Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES Registry. J Clin Oncol. 2013;31:2699\u2013707.","journal-title":"J Clin Oncol"},{"key":"2589_CR23","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.critrevonc.2013.08.009","volume":"89","author":"M Sereno","year":"2014","unstructured":"Sereno M, Guti\u00e9rrez-Guti\u00e9rrez G, G\u00f3mez-Raposo C, L\u00f3pez-G\u00f3mez M, Merino-Salvador M, T\u00e9bar FZ, et al. Oxaliplatin induced-neuropathy in digestive tumors. Crit Rev Oncol Hematol. 2014;89:166\u201378.","journal-title":"Crit Rev Oncol Hematol"},{"key":"2589_CR24","doi-asserted-by":"publisher","first-page":"398","DOI":"10.1080\/0284186X.2018.1556804","volume":"58","author":"LM Soveri","year":"2019","unstructured":"Soveri LM, Lamminm\u00e4ki A, H\u00e4nninen UA, Karhunen M, Bono P, Osterlund P. Long-term neuropathy and quality of life in colorectal cancer patients treated with oxaliplatin containing adjuvant chemotherapy. Acta Oncol Stockh Swed. 2019;58:398\u2013406.","journal-title":"Acta Oncol Stockh Swed"},{"key":"2589_CR25","doi-asserted-by":"publisher","first-page":"1297","DOI":"10.1200\/JCO.2015.65.3048","volume":"34","author":"LA P\u00e5hlman","year":"2016","unstructured":"P\u00e5hlman LA, Hohenberger WM, Matzel K, Sugihara K, Quirke P, Glimelius B. Should the benefit of adjuvant chemotherapy in colon cancer be re-evaluated? J Clin Oncol. 2016;34:1297\u20139.","journal-title":"J Clin Oncol"},{"key":"2589_CR26","doi-asserted-by":"publisher","first-page":"1763","DOI":"10.1200\/JCO.2011.38.3992","volume":"30","author":"NP West","year":"2012","unstructured":"West NP, Kobayashi H, Takahashi K, Perrakis A, Weber K, Hohenberger W, et al. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol. 2012;30:1763\u20139.","journal-title":"J Clin Oncol"},{"key":"2589_CR27","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1016\/S1470-2045(14)71168-4","volume":"16","author":"CA Bertelsen","year":"2015","unstructured":"Bertelsen CA, Neuenschwander AU, Jansen JE, Wilhelmsen M, Kirkegaard-Klitbo A, Tenma JR, et al. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol. 2015;16:161\u20138.","journal-title":"Lancet Oncol"},{"key":"2589_CR28","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s00384-014-1885-z","volume":"29","author":"K Kotake","year":"2014","unstructured":"Kotake K, Mizuguchi T, Moritani K, Wada O, Ozawa H, Oki I, et al. Impact of D3 lymph node dissection on survival for patients with T3 and T4 colon cancer. Int J Color Dis. 2014;29:847\u201352.","journal-title":"Int J Color Dis"},{"key":"2589_CR29","doi-asserted-by":"publisher","first-page":"1479","DOI":"10.1016\/j.ejso.2015.07.019","volume":"41","author":"R Bernhoff","year":"2015","unstructured":"Bernhoff R, Martling A, Sj\u00f6vall A, Granath F, Hohenberger W, Holm T. Improved survival after an educational project on colon cancer management in the county of Stockholm--a population based cohort study. Eur J Surg Oncol. 2015;41:1479\u201384.","journal-title":"Eur J Surg Oncol"},{"key":"2589_CR30","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.ejso.2007.02.003","volume":"33","author":"K Derwinger","year":"2007","unstructured":"Derwinger K, Carlsson G, Gustavsson B. Stage migration in colorectal cancer related to improved lymph node assessment. Eur J Surg Oncol. 2007;33:849\u201353.","journal-title":"Eur J Surg Oncol"},{"key":"2589_CR31","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1016\/S0140-6736(07)61866-2","volume":"370","author":"R Gray","year":"2007","unstructured":"Quasar Collaborative Group, Gray R, Barnwell J, McConkey C, Hills RK, Williams NS, et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet Lond Engl. 2007;370:2020\u20139.","journal-title":"Lancet Lond Engl"},{"key":"2589_CR32","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1056\/NEJMoa1602253","volume":"375","author":"F Cardoso","year":"2016","unstructured":"Cardoso F, van\u2019t Veer LJ, Bogaerts J, Slaets L, Viale G, Delaloge S, et al. 70-gene signature as an aid to treatment decisions in early-stage breast cancer. N Engl J Med. 2016;375:717\u201329.","journal-title":"N Engl J Med"},{"key":"2589_CR33","doi-asserted-by":"publisher","first-page":"1456","DOI":"10.6004\/jnccn.2019.7363","volume":"17","author":"AR Khaki","year":"2019","unstructured":"Khaki AR, Gadi VK, Prasad V. Clinical risk during the evaluation of genomic risk for hormone-sensitive breast cancer: ignoring valuable data. J Natl Compr Cancer Netw. 2019;17:1456\u20138.","journal-title":"J Natl Compr Cancer Netw"},{"key":"2589_CR34","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.annonc.2022.03.273","volume":"33","author":"D Trapani","year":"2022","unstructured":"Trapani D, Franzoi MA, Burstein HJ, Carey LA, Delaloge S, Harbeck N, et al. Risk-adapted modulation through de-intensification of cancer treatments: an ESMO classification. Ann Oncol. 2022;33:702\u201312.","journal-title":"Ann Oncol"},{"key":"2589_CR35","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1016\/S1470-2045(15)70129-4","volume":"16","author":"M Burotto","year":"2015","unstructured":"Burotto M, Prasad V, Fojo T. Non-inferiority trials: why oncologists must remain wary. Lancet Oncol. 2015;16:364\u20136.","journal-title":"Lancet Oncol"},{"key":"2589_CR36","doi-asserted-by":"crossref","unstructured":"Rustin GJS, van der Burg ML, Griffin CL, Guthrie D, Lamont A, Jayson GC, et al. Early versus delayed treatment of relapsed ovarian cancer (MRC OV05\/EORTC 55955): a randomised trial. Lancet. 2010;376(9747):1155-63.","DOI":"10.1016\/S0140-6736(10)61268-8"}],"container-title":["BMC Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12916-022-02589-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12916-022-02589-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T06:01:53Z","timestamp":1694066513000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcmedicine.biomedcentral.com\/articles\/10.1186\/s12916-022-02589-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,9]]},"references-count":36,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["2589"],"URL":"https:\/\/doi.org\/10.1186\/s12916-022-02589-6","relation":{},"ISSN":["1741-7015"],"issn-type":[{"value":"1741-7015","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,9]]},"assertion":[{"value":"10 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 September 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 November 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Because we used publicly available data, and this is not a human subject research in accordance with 45 CFR \u00a746.102(f), we did not submit this study to an institutional review board or require informed consent procedures.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Vinay Prasad\u2019s disclosures: research funding\u2014Arnold Ventures; royalties\u2014Johns Hopkins Press, Medscape; honoraria\u2014Grand Rounds\/lectures from universities, medical centers, non-profits, and professional societies; consulting\u2014UnitedHealthcare; speaking fees\u2014Evicore; others: Plenary Session podcast has Patreon backers. Timoth\u00e9e Olivier declares that there are no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"392"}}